TRUSCREEN ULTRA – THE SMART INVESTMENT
9 years +
After being researched and developed for 27 years, TS was first launched in 2014 to aim for a World Without Cervical Cancer.
TruScreen is used throughout Europe, many developing countries in Asia, and is being developed in the Middle East, Eastern Europe, and Africa markets.
WHO estimates that in 2020, there were 600,000+ new cases of cervical cancer worldwide.
The TruScreen device has been clinically validated on over 20,000 women in multiple settings.